To better understand what might drive the way we live, learn, and work in 2050, we’re asking the community to share their expertise and thoughts about how key factors like research and development infrastructure and automation will shape the trajectory of the ecosystem.
Recognizing the power of the national transportation infrastructure expert community and its distributed expertise, ARPA-I took a different route that would instead bring the full collective brainpower to bear around appropriately ambitious ideas.
NIH needs to seriously invest in both the infrastructure and funding to undertake rigorous nutrition clinical trials, so that we can rapidly improve food and make progress on obesity.
Modernizing ClinicalTrials.gov will empower patients, oncologists, and others to better understand what trials are available, where they are available, and their up-to-date eligibility criteria, using standardized search categories to make them more easily discoverable.
AI safety is a rapidly evolving field that draws attention from a diverse range of policymakers across the political spectrum, including those in Congress, federal agencies, and state and local governments.
From using AI to optimize power grids to accelerating clean energy R&D, AI holds huge potential, while also introducing new challenges related to climate, equity, infrastructure, security, and sustainability.
What steps should the U.S. take to address China’s growing global share of legacy chip manufacturing?
As artificial intelligence evolves, so does the urgency for legislation to manage both the risks and opportunities associated with it.
We engage with the public, academia, and the private sector to foster a broader understanding of AI and emerging technology policy issues.
We’re scoping ambitious ideas to help ARPA-I begin executing projects that improve transportation across the country.
The U.S. bioeconomy is growing rapidly, innovation is needed to sustain and maintain this growth. Shaping policy to consider workforce development, advanced agriculture, bioindustrial and biotech sectors will be imperative to keep the needle moving forward.
We aim to catalyze a more nimble science funding ecosystem, capable of keeping up with and facilitating new innovations to improve the lives of people around the world.
